Russian Heart Failure Journal 2013year Comorbidity and compliance at chronic heart failure

To access this material please log in or register

Register Authorize

Comorbidity and compliance at chronic heart failure

Efremova E. V., Shutov A. М., Sabitov I. A.

Keywords: comorbidity, treatment compliance, psychological status, CHF

DOI: 10.18087/rhfj.2013.1.1782

Relevance. Treatment compliance determines to a large extent CHF treatment efficiency, thus, no due attention is paid to patient’s individual peculiarities (comorbidity) and psychological status peculiarities. Objective. Study clinical and psychological peculiarities of CHF patient compliance considering comorbidity. Materials and methods. 203 patients with CHF were examined (130 male and 73 female, average age 61.8±9.6 years). Comorbidity, psychological status, compliance with non-drug and drug therapy patients with CHF. Results. Charlson comorbidity index with account of age was 4.9±2.1 points. CHF patient compliance to non-drug treatment methods (recommendations on self-control and life style change) was observed in 37 (18.2 %) patients. Compliance to administration of drugs was observed only in 61 (30 %) CHF patients. Patients with poor compliance were characterized by disadaptive type of response, emotional lability, weakness (p<0.04). Inverse relation between CHF duration and compliance (r= –0.32, p<0.001), as well as direct relation between history of MI (r=0.25, p=0.02) and DM (r=0.36, p<0.001) was observed. Conclusion. Comorbidity (except DM type 2) doesn’t influence patient compliance with CHF treatment. Poor treatment compliance is caused by CHF patients’ psychological status peculiarities.
  1. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  2. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33 (14):1787–1847.
  3. Mazzaglia G, Ambrosioni E, Alacqua M et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120 (16):1598–1605.
  4. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119 (23):3028–3035.
  5. Stromberg A. Patient-related factors of complians in heart failure: some new insights an old problem. Eur Heart J. 2006;27 (4):379–381.
  6. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297 (2):177–186.
  7. World Health Organization. Preventing chronic diseases: a vital investment 2005. Available at: / chp / chronic_disease_report / presentation / en / index.html
  8. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of diseasespecific guidelines for patients with multiple conditions. N Engl J Med. 2004;351 (27):2870–2874.
  9. Соломакина Н. И. Сердечная и внесердечная коморбидность у больных систолической и диастолической ХСН пожилого и старческого возраста. Журнал Сердечная недостаточность. 2009;10 (6): 298–233.
  10. Van Weel C, Schellevis FG. Comorbidity and guidelines: conflic­ting interests. Lancet. 2006;367 (9510):550–551.
  11. Карвасарский Б. Д. Клиническая психотерапия в общей врачебной практике. Учебник для вузов – СПб.: «Питер-ЮГ», 2010. – С.150–220.
  12. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012;33 (13):1635–1701.
  13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40 (5):373–383.
  14. Huntley AL, Johnson R, Purdy S et al. Measures of multimorbidity and morbidity burden for use in primary care and community settings: a systematic review and guide. Ann Fam Med. 2012;10 (2):134–141.
  15. Гендлин Г. Е., Самсонова Е. В., Бухало О. В. и др. Методика исследования качества жизни у больных хронической недостаточностью кровообращения. Сердечная недостаточность. 2000;1 (4) 1–12.
  16. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24 (1):67–74.
  17. Леонова М. В., Мясоедова Н. В. Практические аспекты лечения АГ: эффективность и комплаентность. Российский кардиологический журнал. 2003;7 (2):17–21.
  18. Valderas JM, Starfi eld B, Sibbald B et al. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7 (4):357–363.
  19. de Leon CF, Grady KL, Eaton C et al. Quality of life in a diverse population of heart failure patients:Baseline findings from the Heart Failure Adherence and Retention Trial (HART). J Cardiopulm Rehabil Prev. 2009;29 (3):171–178.
  20. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;271 (18):1450–1456.
  21. Salisbury C, Johnson L, Purdy S et al. Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract. 2011;61 (582):e12–21.
  22. Bayliss EA, Steiner JF, Fernald DH et al. Descriptions of bar­riers to self-care by persons with comorbid chronic diseases. Ann Fam Med. 2003;1 (1):15–21.
  23. Dickson VV, Buck H, Riegel B. A qualitative meta-analysis of heart failure self-care practices among individuals with multiple comorbid conditions. J Card Fail. 2011;17 (5):413–419.
  24. Альберт М. А., Биктимиров Т. З., Шутов А. М. Приверженность к лечению и личностные особенности больных с хронической сердечной недостаточностью. Ученые записки Ульяновского государственного университета. 2008;1 (13):6–9.
  25. Rattinger GB, Dutcher SK, Chhabra PT et al. The effect of dementia on medication use and adherence among medicare beneficiaries with chronic heart failure. Am J Geriatr Pharmacother. 2012;10 (1):69–80.
  26. de Leon CF, Grady KL, Eaton C et al. Quality of life in a diverse population of patients with heart failure: BASELINE FINDINGS FROM THE HEART FAILURE ADHERENCE AND RETENTION TRIAL (HART). J Cardiopulm Rehabil Prev. 2009;29 (3):171–178.
  27. Chui MA, Deer M, Bennett SJ et al. Association between adherence to diuretic therapy and health care utilization in patients with heart failure. Pharmacotherapy. 2003;23 (3):326–332.
  28. Holzapfel N, Löwe B, Wild B et al. Self-care and depression in patients with chronic heart failure. Heart Lung. 2009;38 (5):392–397.
Efremova E. V., Shutov A. М., Sabitov I. A. Comorbidity and compliance at chronic heart failure. Russian Heart Failure Journal. 2013;14 (1):40-46

To access this material please log in or register

Register Authorize
Ru En